Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Malignant carcinoid tumors are rare neuroendocrine neoplasms.
• Alpha-interferon is a treatment option for advanced carcinoid tumors.
• Autoimmune complications are a potential concern with long-term immunotherapy.

Purpose of the Study:

• To investigate the incidence of autoantibodies and autoimmune diseases in patients receiving alpha-interferon for malignant carcinoid tumors.
• To assess the impact of these autoimmune phenomena on therapeutic outcomes.

Main Methods:

• A consecutive sample of 135 patients with malignant midgut carcinoid tumors were treated with alpha-interferon.
• Patients were monitored for signs of autoimmune disease and development of autoantibodies (thyroid, nuclear, gastric parietal cells).
• Tumor response was evaluated by changes in liver metastases and urinary 5-hydroxyindole acetic acid levels.

Main Results:

• 19% of patients developed autoimmune disorders, including thyroid disease, lupus erythematosus, pernicious anemia, and vasculitis, after a median of 9 months.
• Thyroid antibodies and antinuclear antibodies were detected in a significant proportion of patients before and during therapy.
• Development of clinical thyroid disease was strongly associated with the presence of thyroid antibodies.

Conclusions:

• Alpha-interferon treatment for malignant carcinoid tumors is associated with an increased risk of developing autoimmune diseases.
• The presence of autoantibodies may predict the development of autoimmune disorders during therapy.
• Autoimmunity did not influence the objective tumor response to alpha-interferon, but monitoring for autoimmune complications is advised.